XAVENE ZAMIC

Dose: 0.143 mg/kg
Single Dose: 0.14 (0.143)
Frequency: 12 hourly
Route: PO
Instructions: Initially for 1 Week

Dose: Not indicated in this age group
Single Dose:
Frequency:
Route:
Instructions:

Dose: Not indicated in this age group
Single Dose:
Frequency:
Route:
Instructions:

Tranylcypromine (Sulphate) also known as Transamine Sulphate. . It is of Synthetic origin and belongs to Phenylcyclopropylamine. It belongs to Psychotherapeutic Drugs and Antidepressant pharmacological group.The Molecular Weight of Tranylcypromine (Sulphate) is 364.50. Its pKa is 8.2.

Tranylcypromine (Sulphate) is contraindicated in conditions like Alcohol dependence,Hyperthyroidism,Phaeochromocytoma,Blood dyscrasias,Liver diseases,Cardiovascular disease,Cerebrovascular disease.

The severe or irreversible adverse effects of Tranylcypromine (Sulphate), which give rise to further complications include Liver dysfunction.Tranylcypromine (Sulphate) produces potentially life-threatening effects which include Severe sympathomimetic crisis. which are responsible for the discontinuation of Tranylcypromine (Sulphate) therapy.The signs and symptoms that are produced after the acute overdosage of Tranylcypromine (Sulphate) include Tachycardia, Convulsions, Fever, Headache, Coma and death, Tachypnea, Agitation, Hypertension, Neuromuscular weakness, Mental confusion, Chest pain.The symptomatic adverse reactions produced by Tranylcypromine (Sulphate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Headache, Drowsiness, Nausea, Restlessness, Palpitation, Weight gain, Peripheral neuropathy, Anticholinergic side effects.

Tranylcypromine (Sulphate) is primarily indicated in conditions like Depression, Neurosis, Psychosis, and can also be given in adjunctive therapy as an alternative drug of choice in Anxiety, Phobias.

Tranylcypromine (Sulphate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlbuterolShould not use concurrently without doctors prescription.Atomoxetine HClSevere adverse reaction is possible in this combination.CarbamazepineChlorpropamideTranylcypromine stimulate the secretion of insulin thus potentiate the hypoglycemic effect of chlorpropamide.ModerateClosely monitor for blood glucose level especially in patient with advanced age and renal impairement.DiazoxideEnhanced hypotensive effect when Diazoxide gven with MAOIs (e.g. Tranylcypromine).Dopamine (HCl)Doxepin.It may couse fever, convulsions and even death.EphedrineEphedrine precipitate the hypertensive crises associated with tranylcypromine by acting synergistically to enhanced norepinephrine storage in adrenergic neurons and increases secretion of catecholamines.MajorCoadministration is considered contraindicated. There should be gap of atleast 14 days between initiation of therapy with ephedrine and discontinuing tranylcypromine.Fenfluramine (HCl)LevodopaMetaraminolCoadministration involve synergistic sympathomimetic effect because metaraminol enhance noradrenaline storage in adrenergic neurons and tranylcypromine increased secretion of catecholamines.In some cases death has been reported.MajorThis combination should not be used or give a gap of atleast 2 weeks after discontinuing tranylcypromine to start metaraminol.MethyldopaNaphazolineConcurrent use may result in interaction. Dosage adjustment or special monitoring during concurrent use is necessary.OxypertineTheoretical potential for OXYPERTINE increasing the CNS STIMULANT effect of TRANYLCYPROMINE. MajorPhentermineConcurrent use may result in high blood pressure.PhenylalaninePhenylalanine supplementation may cause a severe increase in blood pressure in people taking Tranylcypromine (Sulphate).Phenylephrine (HCl)Phenylephrine precipitate the hypertensive crises associated with tranylcypromine by acting synergistically to enhanced norepinephrine storage in adrenergic neurons and increases secretion of catecholamines.MajorCoadministration is considered contraindicated. There should be gap of atleast 14 days between initiation of therapy with phenylephrine and discontinuing tranylcypromine.Pirbuterol (Acetate)Concurrent use may potentiate the action of pirbuterol on the vascular system.Pirbuterol should be administered with extreme caution to patients being treated with Tranylcypromine (Sulphate).Potassium GuaiacolsulphonatePotassium Guaiacolsulphonate should not be used with or within 14 days of taking Tranylcypromine (Sulphate).PropylhexidrinePotential for enhanced sympathomimetic effects. Use concomitantly with caution.Pseudoephedrine (HCl)Rauwolfia ReserpineRizatriptanRizatriptan should not be used within 2 weeks of having used Tranylcypromine (Sulphate).SalmeterolAction of salmeterol on the vascular system may be potentiated by Tranylcypromine (Sulphate). St.Johns Wort ExtractConcurrent use can produce a dangerous rise in blood pressure or hypertensive crisis, along with severe anxiety, fever, muscle tension and confusion.SumatriptanTranylcypromine increases the plasma concentration of sumatriptan by inhibiting their metabolic clearence result in increased risk of vasospastic reactions, including coronory artery vasospasm, peripheral vascular ischemia and clonic ischemia.MajorThis combination is considered contraindicated. There should be gap of at least 14 days between stopping the tranylcypromine and initiation of sumatriptan.Tetrahydrozoline (HCl)Concurrent use may increase the hypertensive effect.Vortioxetine increase toxicity of vortioxetinenever use combination These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Store at room temperature. Protect from Sunlight and Moisture.

Take adequate precautions when treating epileptic patients with tranylcypromine. It should be used with caution in patients with impaired renal (kidney) function and hyperthyroidism. Perform periodic liver function tests, discontinue use at the first sign of liver dysfunction or jaundice.